B Cell Engagers have shown promise in treating various types of cancers, particularly hematological malignancies such as Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin's Lymphoma. For instance, Blinatumomab, a BiTE targeting CD19 on B cells and CD3 on T cells, has been approved for the treatment of relapsed or refractory B-cell precursor ALL. Research is ongoing to expand their applicability to solid tumors and other types of cancer.
